SeqOne Genomics strengthens its Board along with raising €20m Series A funding led by Omnes and Merieux Equity Partners

– FRANCE, Montpellier –  SeqOne Genomics, provider of next genomic analysis solutions for personalized medicine today announced a €20M Series A funding round led by Omnes and Merieux Equity Partners, together with the Software Club and existing investors, Elaia and IRDI Capital Investissement, bringing the total amount raised to date to €23M.

With the closing of this round, SeqOne’s board of directors will be:

  • Dr. Sacha Loiseau, (Ph.D.) independent board Chairman,
  • Fabien Collangettes, Director at Omnes,
  • Yoann Bonnamour, Investment Manager at Merieux Equity Partners,
  • Marc Rougier, Partner at Elaia,
  • Nicolas Philippe, co-founder, and CEO
  • Jean-Marc Holder, Co-founder, and Chief Strategy and Innovation Officer.

The funding will enable SeqOne Genomics to accelerate its international sales and the development of new collaborative genomic analysis tools to facilitate communications between different disciplines in the medical team, to improve patient outcomes in cancer and hereditary disease.

The company will intensify investments in the development of its genomic-aware data lake to improve the use of big data and machine learning approaches in genomic analysis with the aim of better addressing the fast-evolving needs of molecular biology labs that provide genomic analysis in clinical routine environments, as well as to biopharma companies developing new therapies.

SeqOne’s cloud-based solution manages the entire genomic analysis process from raw data to a final report presented to clinicians. The solution’s end-to-end approach affords better analytic performance, high levels of traceability, and improved operational efficiency and has already been adopted by a score of hospitals and central labs and biopharma as well as spawning partnerships with leading manufacturers of genomics analysis hardware and reagents.

Co-founder and CEO, Dr. Nicolas Philippe, said “We are extremely happy to have closed this round with leading investors who bring extensive experience in deep-tech, healthcare, and biotherapy and who share our vision of building SeqOne into a global leader in personalized medicine. The funding will give us the resources we need to enhance and commercialize our solution to make genomic analysis more accessible and affordable so that each patient can benefit from personalized medicine recommendations.”

“The genomics analysis market is experiencing exponential growth driven by the needs of personalized medicine. With the rapid expansion in the available genomic-linked treatments, the complexity of treatment interactions, and the staggering volume of biological and medical data to be factored into each medical decision, biologists and doctors must have access to reliable and actionable analyses in real-time,” commented Fabien Collangettes, Director at Omnes. “We were particularly impressed by SeqOne’s innovative technological approach that enables improved accuracy of the genomic test while reducing turnaround time and cost, thus delivering a key competitive advantage in this fast-growing market.”

About SeqOne Genomics

SeqOne Genomics offers high-performance genomic analysis solutions for healthcare providers treating patients suffering from cancer, rare and hereditary diseases as well as pharmaceutical companies developing new therapies. The solution leverages advanced machine learning coupled with the company’s proprietary GeniOS™ genomics operating system to dramatically reduce turnaround times and costs while delivering comprehensive and actionable insights for personalized medicine. The company has won numerous awards including the iLab award and the ARC cancer foundation’s Hélène Stark prize. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club.

The company currently employs over 40 staff, primarily experts in genomic medicine, data science, bioinformatics, software development, and regulatory compliance/quality assurance. It plans to double its staff within the year to execute its ambitious plans.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.